Antibodies against human or mouse IL-21 receptor
US7495085B2 · kind B2 · utility
11Cited by
20References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 12, 2004 |
| Grant date | Feb 24, 2009 |
| Priority date | — |
| Expiry date | Nov 30, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/622
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.